2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Wednesday, November 16, 2016

9:00AM-10:30AM: Abstract Number: 3135

Influence of Baseline Magnetic Resonance Imaging Features on Outcomes of Operative and Non-Operative Treatment of Meniscal Tear in Patients ≥ 45

Osteoarthritis – Clinical Aspect II: Treatment and Imaging

9:00AM-10:30AM: Abstract Number: 3175

Longitudinal Analysis of MMF Clinical, Molecular, and Immunohistochemistry (IHC) Responses Shows SSc Patients Lose Their Inflammatory Signature and Rebound upon Treatment Cessation

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Pathogenesis, Animal Models and Genetics II

9:00AM-10:30AM: Abstract Number: 3176

Meta-Analysis of SSc Clinical Trials with Molecular Gene Expression Data Suggests Potential Combination Therapies

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Pathogenesis, Animal Models and Genetics II

9:00AM-10:30AM: Abstract Number: 3169

Mortality Trends in Systemic Lupus Erythematosus: A General Population-Based Cohort Study

Systemic Lupus Erythematosus – Clinical Aspects and Treatment V: Damage and Morbidity

9:00AM-10:30AM: Abstract Number: 3173

Pan-PPAR Agonist IVA337 Is Effective in the Prevention of Experimental Lung Fibrosis and Related Pulmonary Hypertension

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Pathogenesis, Animal Models and Genetics II

9:00AM-10:30AM: Abstract Number: 3148

Peptidylarginine Deiminase 2 Is Required for Tumor Necrosis Factor Alpha Induced Citrullination and Arthritis, but Not Neutrophil Extracellular Trap Formation

Rheumatoid Arthritis – Animal Models II

9:00AM-10:30AM: Abstract Number: 3131

Pregabalin Is More Effective in Treating Hand Osteoarthritis Pain Than Duloxetine or Placebo: A Double-Blind Randomized Controlled Trial

Osteoarthritis – Clinical Aspect II: Treatment and Imaging

9:00AM-10:30AM: Abstract Number: 3132

Protective Effects of Replacing Sedentary Time with Light and Moderate to Vigorous Physical Activity on Functional Limitation in Knee OA

Osteoarthritis – Clinical Aspect II: Treatment and Imaging

9:00AM-10:30AM: Abstract Number: 3120

RA Net: A Systems Biology Approach to Identify Genes Regulating Pathogenic Pathways in Rheumatoid Arthritis (RA) Fibroblast-like Synoviocytes (FLS)

Genetics, Genomics and Proteomics II

9:00AM-10:30AM: Abstract Number: 3123

Rare Mediterranean Fever (MEFV) Gene Polymorphisms Are Associated with Ankylosing Spondylitis in Turkish and Iranian Population

Genetics, Genomics and Proteomics II

9:00AM-10:30AM: Abstract Number: 3115

Reconsidering the Juvenile Idiopathic Arthritis Core Set: How Patients and Caregivers Define Disease Activity

ACR/ARHP Combined Abstract Session: Pediatric Rheumatology

9:00AM-10:30AM: Abstract Number: 3147

Remote Inflammation Triggers Autoimmune Arthritis through Th17 Distribution

Rheumatoid Arthritis – Animal Models II

9:00AM-10:30AM: Abstract Number: 3152

Rheumatoid Arthritis (RA): Premature Use of Biologics Accelerating in United States (US)

Rheumatoid Arthritis – Clinical Aspects VI: Management of Early Rheumatoid Arthritis

9:00AM-10:30AM: Abstract Number: 3116

Risk of Infections in Juvenile Idiopathic Arthritis Patients Treated with Biologic Agentsand/or Methotrexate: Results from Pharmachild Registry

ACR/ARHP Combined Abstract Session: Pediatric Rheumatology

9:00AM-10:30AM: Abstract Number: 3144

Role of the Gut Microbiome in Modulating Arthritis Progression in Mice

Rheumatoid Arthritis – Animal Models II

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].